CR20250051A - Agonista dual de glp-1/gip, método de preparación y uso del mismo - Google Patents

Agonista dual de glp-1/gip, método de preparación y uso del mismo

Info

Publication number
CR20250051A
CR20250051A CR20250051A CR20250051A CR20250051A CR 20250051 A CR20250051 A CR 20250051A CR 20250051 A CR20250051 A CR 20250051A CR 20250051 A CR20250051 A CR 20250051A CR 20250051 A CR20250051 A CR 20250051A
Authority
CR
Costa Rica
Prior art keywords
glp
gip
preparation
dual agonist
receptor
Prior art date
Application number
CR20250051A
Other languages
English (en)
Inventor
Zhang Nan
Jiang Chunhua
Teng Li
Liu Dongzhou
Shen Jiale
Original Assignee
Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd filed Critical Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd
Publication of CR20250051A publication Critical patent/CR20250051A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

La presente invención se relaciona con compuestos agonistas duales de GLP-1/GIP de larga duración que tienen un efecto agonista dual en el receptor del péptido-1 de tipo glucagon (GLP-1) y el receptor del polipéptido insulinotrópico dependiente de la glucosa (GIP) humano. La presente invención también se relaciona con el uso de dichos compuestos en la fabricación de medicamentos para tratar diabetes mellitus de Tipo II.
CR20250051A 2022-07-13 2023-07-12 Agonista dual de glp-1/gip, método de preparación y uso del mismo CR20250051A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202210825092 2022-07-13
CN202211266927 2022-10-17
CN202310096643 2023-01-18
PCT/CN2023/106879 WO2024012472A1 (zh) 2022-07-13 2023-07-12 Glp-1/gip双激动剂及其制备方法和用途

Publications (1)

Publication Number Publication Date
CR20250051A true CR20250051A (es) 2025-03-18

Family

ID=89498864

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250051A CR20250051A (es) 2022-07-13 2023-07-12 Agonista dual de glp-1/gip, método de preparación y uso del mismo

Country Status (17)

Country Link
US (1) US12589158B2 (es)
EP (1) EP4556487A1 (es)
JP (1) JP2025523681A (es)
KR (1) KR20250037523A (es)
CN (3) CN117402219B (es)
AR (1) AR129903A1 (es)
AU (1) AU2023305663A1 (es)
CL (1) CL2025000088A1 (es)
CO (1) CO2025001430A2 (es)
CR (1) CR20250051A (es)
DO (1) DOP2025000003A (es)
IL (1) IL318349A (es)
MX (1) MX2025000531A (es)
PE (1) PE20251259A1 (es)
TW (1) TW202411244A (es)
UY (1) UY40349A (es)
WO (1) WO2024012472A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202542174A (zh) * 2023-12-29 2025-11-01 大陸商杭州中美華東製藥有限公司 Glp-1/gip雙激動劑的固相合成方法
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025161155A1 (zh) * 2024-02-04 2025-08-07 内蒙古博睿精创科技有限公司 一种长效glp-1多肽化合物、组合物及其应用
WO2025237168A1 (zh) * 2024-05-11 2025-11-20 石药集团百克(山东)生物制药股份有限公司 Gipr和glp-1r共激动多肽及其用途
CN118440155B (zh) * 2024-07-11 2024-11-22 中国药科大学 一种双激动多肽化合物及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
AR096440A1 (es) * 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
WO2016077806A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion proteins with dual receptor agonist activities
JO3575B1 (ar) 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
TWI735917B (zh) * 2018-07-23 2021-08-11 美商美國禮來大藥廠 Gip/glp1共促效劑化合物
MX2021006505A (es) * 2018-12-03 2021-10-01 Antag Therapeutics Aps Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
CN111825758B (zh) * 2019-04-19 2024-11-22 上海翰森生物医药科技有限公司 Glp-1和gip共激动剂化合物
WO2021093883A1 (zh) * 2019-11-15 2021-05-20 江苏豪森药业集团有限公司 双受体重激动剂化合物及其药物组合物
CN114761420B (zh) * 2019-12-03 2026-04-28 安泰博医药 优化的gip肽类似物
BR112022023834A2 (pt) * 2020-05-29 2022-12-27 Beijing Tuo Jie Biopharmaceutical Co Ltd Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo
AU2021312323A1 (en) * 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
CA3184723A1 (en) * 2020-07-22 2022-01-27 Patrick J. KNERR Glp-1 and gip receptor co-agonists
BR112023003668A2 (pt) * 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
CN114349828B (zh) * 2020-11-27 2023-12-08 江苏师范大学 Glp-1/胰高血糖素受体双重激动剂及其应用

Also Published As

Publication number Publication date
IL318349A (en) 2025-03-01
JP2025523681A (ja) 2025-07-23
AR129903A1 (es) 2024-10-09
US20240325549A1 (en) 2024-10-03
TW202411244A (zh) 2024-03-16
CL2025000088A1 (es) 2025-05-30
PE20251259A1 (es) 2025-05-06
KR20250037523A (ko) 2025-03-17
WO2024012472A1 (zh) 2024-01-18
CN117402219B (zh) 2024-07-30
AU2023305663A1 (en) 2025-02-20
CN119522233A (zh) 2025-02-25
CO2025001430A2 (es) 2025-03-17
US12589158B2 (en) 2026-03-31
UY40349A (es) 2024-01-31
DOP2025000003A (es) 2025-02-28
EP4556487A1 (en) 2025-05-21
CN117402219A (zh) 2024-01-16
CN119080887A (zh) 2024-12-06
MX2025000531A (es) 2025-02-10

Similar Documents

Publication Publication Date Title
CO2025001430A2 (es) Agonista dual de glp-1/gip, método de preparación y uso del mismo
BR112023003668A2 (pt) Agonistas duplos de glp-1/gip
Gasbjerg et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
DOP2017000153A (es) Compuestos co-agonistas de gip y glp-1
BR112022025615A2 (pt) Agonistas duplos de glp-1/gip de ação prolongada
ZA202106369B (en) Gip/glp1 co-agonist compounds
BR112021020071A2 (pt) Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos
AR121093A1 (es) Compuestos coagonistas de gip / glp1
MX2023000303A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
AR084558A1 (es) Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
JOP20220153A1 (ar) نظائر الإنكرتين واستخداماتها
BR112023024968A2 (pt) Tratamento da obesidade e distúrbios relacionados à obesidade
MX2026000195A (es) Triagonista de los receptores glp-1, gip y gcg y su uso
ECSP23019850A (es) Agonistas duales glp-1/gip
EA202092891A1 (ru) Соединения-коагонисты gip/glp1